Matching articles for "Issue 1290"

Correction: The EarCheck Middle Ear Monitor

   
The Medical Letter on Drugs and Therapeutics • August 11, 2008;  (Issue 1292)
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic...
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
Med Lett Drugs Ther. 2008 Aug 11;50(1292):64 | Show Full IntroductionHide Full Introduction

Varenicline (Chantix) Warnings: Risk Versus Benefit

   
The Medical Letter on Drugs and Therapeutics • July 14, 2008;  (Issue 1290)
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about...
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):53 | Show Full IntroductionHide Full Introduction

Lubiprostone (Amitiza) for Irritable Bowel Syndrome with Constipation

   
The Medical Letter on Drugs and Therapeutics • July 14, 2008;  (Issue 1290)
Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with...
Lubiprostone (Amitiza), which was previously approved for treatment of chronic idiopathic constipation in adults, has now also been approved in a lower dose for use in women with irritable bowel syndrome with constipation (IBS-C). Since tegaserod (Zelnorm) has been withdrawn from the market,2 lubiprostone is the only drug approved by the FDA for treatment of this common condition.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):53-4 | Show Full IntroductionHide Full Introduction

Wellbutrin Versus Generic Bupropion

   
The Medical Letter on Drugs and Therapeutics • July 14, 2008;  (Issue 1290)
Bupropion (Wellbutrin - GlaxoSmithKline, and others) is a norepinephrine and dopamine reuptake inhibitor that has been a useful antidepressant because, unlike some other antidepressants, it does not cause...
Bupropion (Wellbutrin - GlaxoSmithKline, and others) is a norepinephrine and dopamine reuptake inhibitor that has been a useful antidepressant because, unlike some other antidepressants, it does not cause sexual dysfunction, weight gain or sedation. Some patients who were switched from Wellbutrin to a generic alternative have reported worsening side effects and relapse of previously controlled depressive symptoms.1 Most of the complaints have come from patients switched from Wellbutrin XL 300 mg to the generic 300-mg formulation of extended-release bupropion marketed by Teva (Budeprion XL).2 In 2007, about 1 million prescriptions per month were dispensed for extended-release formulations of bupropion; about 40% of these were written for Budeprion XL 300 mg.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):54-5 | Show Full IntroductionHide Full Introduction

The EarCheck Middle Ear Monitor for Detection of Middle Ear Effusion in Children

   
The Medical Letter on Drugs and Therapeutics • July 14, 2008;  (Issue 1290)
The EarCheck Middle Ear Monitor (Innovia Medical) is a device marketed to consumers for home detection of middle-ear effusion (MEE) in...
The EarCheck Middle Ear Monitor (Innovia Medical) is a device marketed to consumers for home detection of middle-ear effusion (MEE) in children.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):55-6 | Show Full IntroductionHide Full Introduction